Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Monday

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Monday, February 24th. Analysts expect Theravance Biopharma to post earnings of ($0.05) per share and revenue of $29.90 million for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.

Theravance Biopharma Stock Down 0.9 %

Shares of TBPH stock traded down $0.09 on Thursday, reaching $9.66. The company had a trading volume of 234,075 shares, compared to its average volume of 191,884. The stock has a market capitalization of $474.98 million, a PE ratio of -9.56 and a beta of 0.21. Theravance Biopharma has a one year low of $7.44 and a one year high of $10.90. The business's 50-day moving average is $9.41 and its 200 day moving average is $8.88.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now owns 309,565 shares of the company's stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.90% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.